
Arterial Remodeling Technologies
closedART – Arterial Remodeling Technologies | art-stent.
EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | (28772 %) | - | - | - | - | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | (27841 %) | - | - | - | - | - |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Arterial Remodeling Technologies (ART) specializes in the development of bioresorbable stent platforms designed for coronary artery disease treatment. The company operates in the medical device sector, focusing on innovative solutions for cardiovascular health. ART's core product, the Pure Bioresorbable Scaffold (PBS), offers effective scaffolding for blocked arteries, followed by a programmed dismantling process that allows for positive remodeling and complete resorption within 24 months. This approach aims to improve patient outcomes by reducing long-term complications associated with permanent stents. ART primarily serves healthcare providers and medical institutions involved in interventional cardiology. The business model revolves around the development and commercialization of its proprietary PLA platform technology, which features tunable dismantling and material-preserving transformation processes. Revenue is generated through the sale of its stent products to hospitals and clinics, as well as potential partnerships with larger medical device companies. Key milestones include successful preclinical trials and the first human implantation of its biodegradable stent, demonstrating proven safety and efficacy. Keywords: bioresorbable, stent, coronary, artery, remodeling, scaffold, dismantling, resorption, cardiovascular, healthcare.